InvestorsHub Logo
Followers 72
Posts 4827
Boards Moderated 0
Alias Born 01/24/2004

Re: patientlywaiting post# 86333

Friday, 08/10/2012 1:57:11 PM

Friday, August 10, 2012 1:57:11 PM

Post# of 346054
WOW, they’re doing Stifel Nicolaus again this year – I checked 1hr. ago, and it wasn’t there… Thanks, PW.

Sept5-6 2012: “Stifel Nicolaus Healthcare Conf.”, Boston
”Our conferences are designed to connect the dots and provide original perspective and depth of insight that are rare at most investor conferences. The goal of each conference is to provide institutional investors with high-level access to senior management and industry experts, showcase dynamic emerging companies and investigate critical trends that are driving our economy.”
http://www.tweisel.com/Stifel/ConferencesAndEvents
WEBCAST link: xxxxxxx
Stifel Healthcare IB: http://www2.stifel.com/site/content.aspx?id=206

9-8-2011: CEO Steve King presents at Stifel Nicolaus HC/Boston - a few slides, incl. milestones: http://tinyurl.com/3sk8rba

- - - - - - - - - - - - - - - - - - - - - - -
Aug15 10:55am: Wedbush Life Sciences Mgt. Access Conf., NYC http://tinyurl.com/c6hadmy

Sep5-6: Stifel Nicolaus Healthcare Conf., Boston http://www.tweisel.com/Stifel/ConferencesAndEvents

Sep7: Chicago Symposium in Thoracic Oncology http://tinyurl.com/92oazbv
…1:40-1:50pm/talk, Dr. David Gerber, "Randomized, Double-Blind, Placebo-Ctl'd Ph2 Trial of Bavi+Doce in 2nd-Line Adv. NSCLC (Top-line Results)"
...5:30-6:30pm/poster, Dr. David Gerber, "Association Between Baseline Tumor Diameters & Overall Survival in Patients with Advanced NSCLC” (#116)

~Sep10: FY'13/Q1 (q/e 7-31-12) Financials & Conf. Call

Oct8-12/AVID(#618): IBC's BioProcess Intl. Conf. & Exhibition/ProvidenceRI http://www.ibclifesciences.com/BPI

~Oct18: Annual Shareholder's Meeting

Dec5: IBC's 23rd Annual Intl. Conf - Antibody Eng. & Therapeutics (SDiego) http://tinyurl.com/csdng4h
...11:00 Dr. Philip Thorpe (Chair) "Overcoming Immune Suppression in Tumors with Bavituximab: Preclinical Studies"
…11:30 Joe Shan (PPHM's VP/Reg.Affairs), "Clinical Dev. of Bavituximab, a PS-Targeting Mab"

~Dec10: FY'13/Q2 (q/e 10-31-12) Financials & Conf. Call
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News